Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 4 of 4 items for :

Clear All
Pepijn van Houten Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Pepijn van Houten in
Google Scholar
PubMed Close
,
James Nagarajah Roentgeninstitut Duesseldorf, Duesseldorf, Germany
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by James Nagarajah in
Google Scholar
PubMed Close
,
Janneke E W Walraven Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Janneke E W Walraven in
Google Scholar
PubMed Close
,
Martin Jaeger Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Martin Jaeger in
Google Scholar
PubMed Close
,
Adriana C H van Engen-van Grunsven Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Adriana C H van Engen-van Grunsven in
Google Scholar
PubMed Close
,
Johannes W Smit Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Johannes W Smit in
Google Scholar
PubMed Close
, and
Romana T Netea-Maier Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed Close

accompanied by non-negligible side effects. Moreover, not all RAI-refractory NMTC patients harbor established mutations that make them eligible for treatment with these inhibitors. Preclinical studies have demonstrated that the cardiac glycoside digoxin

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-24-0153
Volume/Issue:
Volume 13: Issue 4
Open access
Ulrich Schweizer Institut für Biochemie und Molekularbiologie, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany

Search for other papers by Ulrich Schweizer in
Google Scholar
PubMed Close
,
Jörg Johannes Institut für Experimentelle Endokrinologie, Charité-Universitätsmedizin Berlin, Berlin, Germany

Search for other papers by Jörg Johannes in
Google Scholar
PubMed Close
,
Dorothea Bayer Institut für Biochemie und Molekularbiologie, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany

Search for other papers by Dorothea Bayer in
Google Scholar
PubMed Close
, and
Doreen Braun Institut für Biochemie und Molekularbiologie, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany

Search for other papers by Doreen Braun in
Google Scholar
PubMed Close

, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000367858
Volume/Issue:
Volume 3: Issue 3
Free access
George J. Kahaly Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany

Search for other papers by George J. Kahaly in
Google Scholar
PubMed Close
,
Luigi Bartalena Department of Medicine and Surgery, University of Insubria, Varese, Italy

Search for other papers by Luigi Bartalena in
Google Scholar
PubMed Close
,
Lazlo Hegedüs Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

Search for other papers by Lazlo Hegedüs in
Google Scholar
PubMed Close
,
Laurence Leenhardt Thyroid and Endocrine Tumors Unit, Pitié Salpêtrière Hospital, Sorbonne University, Paris, France

Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed Close
,
Kris Poppe Endocrine Unit, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium

Search for other papers by Kris Poppe in
Google Scholar
PubMed Close
, and
Simon H. Pearce Department of Endocrinology, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

Search for other papers by Simon H. Pearce in
Google Scholar
PubMed Close

patients with asthma. Anticoagulation with warfarin or direct oral anticoagulants should be considered in all patients with atrial fibrillation. If digoxin is used, increased doses are often needed in the thyrotoxic state [ 2 , 5 , 6 , 72

Article Type:
Guideline
DOI:
https://doi.org/10.1159/000490384
Volume/Issue:
Volume 7: Issue 4
Free access
Georgios Kostopoulos Department of Endocrinology and Metabolism, Ippokratio General Hospital of Thessaloniki, Greece

Search for other papers by Georgios Kostopoulos in
Google Scholar
PubMed Close
and
Grigoris Effraimidis Department of Endocrinology and Metabolic Diseases, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Search for other papers by Grigoris Effraimidis in
Google Scholar
PubMed Close

significant sustained beta-adrenoceptor blockade and offering the potential for better compliance ( 52 ). In case of contradictions (e.g. asthma and chronic obstructive pulmonary disease), other agents can be used instead (calcium-channel blockers, digoxin

Article Type:
Review Article
Collections:
Hyperthyroidism and thyrotoxicosis
DOI:
https://doi.org/10.1530/ETJ-23-0254
Volume/Issue:
Volume 13: Issue 2
Open access